MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor

In: Clinical Lymphoma Myeloma and Leukemia · 2022 · vol. 22 , pp. S339–S340 · doi:10.1016/s2152-2650(22)01463-x · W4296468442
OA: closed CC0 ⤵ 1 in-corpus citation
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-14 ⓘ

The MOMENTUM trial randomized symptomatic and anemic myelofibrosis patients previously treated with a JAK inhibitor to receive either momelotinib or danazol.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

openalex
last seen: 2026-05-10T11:12:16.133615+00:00
unpaywall
last seen: 2026-11-05T06:08:55.941966+00:00
License: CC0 · commercial use OK